Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
RegenScientific is a biotechnology company focused on the development and commercialization of autologous regenerative medicine therapies. Operating as the U.S. arm of the Swiss firm Regen Lab SA, the company specializes in Platelet-Rich Plasma (PRP) and hyaluronic acid-based products for medical aesthetics and musculoskeletal health. Their core technology involves patented, closed-circuit systems that allow for the standardized preparation of bioactive proteins and cells from a patient's own blood. Key products include Renova for dermal filling and ArthroVisc for orthopedic applications, both of which leverage the body's natural healing mechanisms. The company's solutions are widely utilized in sports medicine, dermatology, and wound management to promote tissue repair and reduce inflammation. RegenScientific emphasizes point-of-care delivery, providing clinicians with the tools to prepare high-quality biologics efficiently.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on RegenScientific.